Published by Jamie JemmesonAustralia's specialist pharmaceuticals and vaccine group CSL has warned that its profits will be hurt by the rise in the Australian dollar.However, managing director Brian McNamee assured that, as the world's second largest blood products group, CSL will continue to enjoy strong international payments receipts from overseas operations, from where it derives 90 per cent of its profits.His comments came at the company's annual shareholders' meeting and he warned attendees that the dollar is unlikely to move from its current highs "for a while".Reuters quoted him as saying the company is "really hopeful that big markets in Asia can grow over the next few years".Emerging market currencies in Asia have also rallied in recent weeks as the US dollar has slumped to a 15-year low against the yen and touched new lows against a basket of other currencies.Last week the dollar hit an eight-month low against the euro in global forex trading.For more information on international payments, visit our Smart FX site.